Cargando…

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jiyu, Cui, Shuang, He, Qingxian, Guo, Yitong, Pan, Xiaojie, Zhang, Pengfei, Huang, Ningning, Ge, Chaoliang, Wang, Guangji, Gonzalez, Frank J., Wang, Hong, Hao, Haiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957516/ https://www.ncbi.nlm.nih.gov/pubmed/31932588 http://dx.doi.org/10.1038/s41467-019-14138-6

Ejemplares similares

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR
por: Cui, Shuang, et al.
Publicado: (2023)

Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
por: Wang, Hong, et al.
Publicado: (2018)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats
por: Wang, Jie-ping, et al.
Publicado: (2022)

Natural Product 2-Oxokolavenol Is a Novel FXR Agonist
por: Guo, Fusheng, et al.
Publicado: (2022)

Repression of intestinal transporters and FXR-FGF15 signaling explains bile acids dysregulation in experimental colitis-associated colon cancer
por: Cao, Lijuan, et al.
Publicado: (2017)

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
por: Schwabl, Philipp, et al.
Publicado: (2021)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
por: Deuschle, Ulrich, et al.
Publicado: (2012)

Bacteriophages Synergize with the Gut Microbial Community To Combat Salmonella
por: Hu, Yue O. O., et al.
Publicado: (2018)

CPP–ACP and Fluoride: A Synergism to Combat Caries
por: Attiguppe, Prabhakar, et al.
Publicado: (2019)

PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis
por: Zhou, Xueyan, et al.
Publicado: (2014)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
por: An, Ping, et al.
Publicado: (2020)

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
por: Carino, Adriana, et al.
Publicado: (2017)

Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation
por: Schuster, Daniela, et al.
Publicado: (2011)

Alcoholic liver steatosis in mice is aggravated by low-protein diet and reversed by FXR agonist
por: Lívero, Francislaine Aparecida dos Reis, et al.
Publicado: (2012)

Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches
por: Chen, Meimei, et al.
Publicado: (2016)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
por: Miyata, Sachiho, et al.
Publicado: (2021)

Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis
por: Miyazaki, Tsuneyuki, et al.
Publicado: (2021)

Stat3 role in the protective effect of FXR Agonist in parenteral nutrition-associated cholestasis
por: Ghosh, Swati, et al.
Publicado: (2023)

Bile Acids, Microbiota, and Cystic Fibrosis: Channeling Intestinal FXR Signals
por: McHenry, Scott, et al.
Publicado: (2019)

Natural Products Against Renal Fibrosis via Modulation of SUMOylation
por: Liu, Peng, et al.
Publicado: (2022)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
por: Lu, Lu, et al.
Publicado: (2023)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

An extract from date palm fruit (Phoenix dactylifera) acts as a co-agonist ligand for the nuclear receptor FXR and differentially modulates FXR target-gene expression in vitro
por: Alfaro-Viquez, Emilia, et al.
Publicado: (2018)

Combating Kidney Fibrosis
por: Kanasaki, Keizo, et al.
Publicado: (2014)

Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum
por: Grienke, Ulrike, et al.
Publicado: (2011)

Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
por: Sepe, Valentina, et al.
Publicado: (2016)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (−)-Fargesone A as a Novel FXR Agonist
por: Guo, Fusheng, et al.
Publicado: (2022)

FXR expression in rats of hilar cholangiocarcinoma
por: Zhang, Meng-yu, et al.
Publicado: (2022)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

Activation of FXR protects against renal fibrosis via suppressing Smad3 expression
por: Zhao, Kai, et al.
Publicado: (2016)

Investigating the Mechanisms of Jieduquyuziyin Prescription Improves Lupus Nephritis and Fibrosis via FXR in MRL/lpr Mice
por: Liu, Jingqun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gk999s0g1ts05251ldb6p0ogm4